India Unveils Quantum Microscope and 1st Liquid Helium Cryogenic Facility at IIT Bombay, Pioneering Cancer Diagnosis Breakthroughs

India has inaugurated its first Liquid Helium Cryogenic Facility at IIT Bombay, alongside advances in quantum sensing technologies, which are expected to play a transformative role in medical imaging and cancer diagnosis.

Union Minister Dr. Jitendra Singh inaugurated the Liquid Helium Facility at IIT Bombay, calling it a milestone in India’s quantum ecosystem. The facility includes a helium recovery system that reduces cryogenic experiment costs to one-tenth while conserving helium, a rare global resource.

The Minister dedicated the facility to the nation and reviewed India’s first indigenous quantum sensing and imaging platforms. Among them was QMagPI, a portable magnetometer capable of detecting ultra-low magnetic fields at the nanotesla scale.

Quantum Lab at #IITBombay, supported by the Department of Science & Technology (#DST) under the National Quantum Mission #NQM, is the first of its kind in the country.

Quantum Diamond Microscope and Quantum MagPi are cutting edge breakthroughs with diverse applications,… pic.twitter.com/nki3Wi6ZoU

— Dr Jitendra Singh (@DrJitendraSingh) November 24, 2025

---

Key highlights of the announcement

• Liquid Helium Cryogenic Facility: India’s first such installation, dedicated at IIT Bombay, enables ultra-low temperature experiments essential for quantum research.
• Quantum Microscope Potential: Quantum sensing breakthroughs at IIT Bombay are being positioned as tools for high-resolution medical imaging, which could significantly improve early cancer detection.
• Government Backing: Union Minister Dr. Jitendra Singh emphasized that this initiative reflects India’s commitment to building a strong ecosystem in quantum science, cryogenics, advanced materials, and next-generation computing.
• Cancer Diagnosis Applications: Quantum microscopes, when paired with cryogenic environments, can reduce noise and enhance sensitivity, allowing researchers to observe biological samples at unprecedented resolution. This could lead to earlier and more accurate cancer diagnostics compared to conventional imaging.

---

Why this matters

• Medical Breakthroughs: Traditional microscopes often struggle with resolution limits. Quantum microscopes, leveraging entangled photons and cryogenic cooling, can surpass these barriers.
• Cryogenics in Healthcare: Liquid helium cooling stabilizes quantum sensors, making them reliable for clinical applications. This is crucial for biopsy-free cancer detection and precision medicine.
• Global Competitiveness: India joins the ranks of countries investing heavily in quantum-enabled healthcare, positioning itself as a leader in quantum medical technology.

---

Challenges and next steps

• Infrastructure Costs: Cryogenic facilities are expensive to maintain, requiring continuous helium supply and specialized expertise.
• Clinical Translation: Moving from lab-based quantum sensing to hospital-ready diagnostic tools will demand regulatory approvals, clinical trials, and interdisciplinary collaboration.
• Talent Pipeline: India will need to train more quantum engineers, medical physicists, and biotechnologists to fully harness this innovation.

---

Broader implications

This development is not just about cancer diagnosis—it signals India’s ambition to integrate quantum technologies into healthcare, computing, and materials science. If successful, quantum microscopes could revolutionize how diseases are detected and treated, while cryogenic facilities will serve as the backbone for future quantum computing and sensing ecosystems.

4baseCare Launches New Genomics Lab in Bengaluru, Unveils Global Cancer Diversity Atlas

4baseCare, a precision oncology company, inaugurated its new genomics laboratory in Mahadevapura, Bengaluru, as a part of its consistent efforts to advance access to precision oncology in India. The highlight of the launch event was the unveiling of Global Cancer Diversity Atlas (GCDA) aimed at addressing the genomics data gap that exists in cancer care.

The launch event was presided over by Mr. N. R. Narayana Murthy, Chairman, Infosys, who also unveiled the Global Cancer Diversity Atlas. In attendance were Ganapathy Subramaniam, Founding Managing Partner at Yali Capital, Rajan Anandan, Managing Director , Peak XV Partners, and founders of 4baseCare, Hitesh Goswami and Kshitij Rishi.

 

4baseCare’s new genomics lab in Bengaluru will offer advanced genomic testing solutions including comprehensive gene panels, whole exome sequencing, and transcriptome analysis. These tools will enable oncologists to delve deeper into the genetic makeup of tumors, offering personalized and more effective cancer treatment options.

The Global Cancer Diversity Atlas (GCDA) is a pioneering initiative by 4baseCare designed to address a critical gap in global cancer research: the lack of genomic data from diverse populations. While most cancer genomic datasets are dominated by Western populations, GCDA is built on real-world data from India and the Global South, including South Asia, Southeast Asia, the Middle East, Central Europe, and Latin America. GCDA is the world’s most inclusive cancer genomics dataset, transforming how we develop diagnostics, conduct research, and deliver cancer care so that every patient, everywhere, is truly seen and understood.

Commenting on the new lab and the unveiling of GCDA, Hitesh Goswami, CEO and Co-Founder, 4baseCare, said, “Our new genomics lab and the unveiling of the GCDA are driven by a single goal of creating better access to precision oncology. One of the key challenges in cancer care today is the lack of genomic data from Indian and Asian populations. This data gap has a significant impact on the effectiveness of cancer diagnostics and treatment strategies for under-represented communities.”

“At 4baseCare, we have firsthand seen the kind of real-world impact our genetic tests have had on cancer patients because of the right genomic data sets. Through our lab, we are creating an infrastructure to build population-specific genomic data at scale. And with GCDA, our aim is to close the diversity gap in cancer research that can change how cancer diagnosis and treatment is approached worldwide”, Hitesh added.

About 4baseCare

Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare has been a pioneer in launching unique solutions in cancer care to support oncologists match patients with the right targeted therapy based on biomarker identification. 4baseCare’s best-in-class genomic-based tests include #IndiaKaGenePanel, Indiegene which is the world's first Indian population specific cancer gene panel for biomarker testing.

4baseCare is an Illumina accelerator company, backed by Infosys Innovation fund. 4baseCare also secured 6 million in series A funding round from Yali Capital, is the first Asia/Pacific company to be selected for Illumina’s accelerator program in 2019. 4baseCare has also been awarded a 5 Million INR Biotechnology Ignition Grant (BIG), a flagship scheme of Biotechnology Industry Research Assistance Council (Biotechnology Industry Research Assistance Council (BIRAC), a Public Sector Undertaking the Department of Biotechnology, Government of India. Very recently,

4baseCare has expanded its global footprint by launching operations in Dubai by establishing a state-of-the-art genomics laboratory at Dubai Science Park, in collaboration with Innovate Life Sciences. The facility has recently earned CAP Accreditation. Strengthening its international presence, the company inaugurated a new lab in the Philippines in May 2025, in partnership with LINCs Philippines.

For more details, visit, https://4basecare.com/

Reliance Industries Acquires Tech-driven Oncology Platform Karkinos Healthcare for Rs 375 Cr

Reliance Industries, through its wholly-owned subsidiary Reliance Strategic Business Ventures (RSBVL), has acquired the oncology-focused healthcare platform Karkinos Healthcare for ₹375 crore.

Incorporated in July 2020, Karkinos Healthcare is an oncology-focused healthcare platform that specializes in early cancer detection and treatment using technology-driven solutions.

Here are some key details about the acquisition:

• Date of Acquisition: The acquisition was completed on December 27, 2024.
• Nature of Business: Karkinos specializes in early cancer detection and treatment using technology-driven solutions.
• Turnover: Karkinos reported a turnover of ₹22 crore for the fiscal year 2022-23.
• Investors: Prominent past investors included Tata Sons, Reliance Digital Health Ltd, Mayo Clinic, Sundar Raman, and Ravi Kant.
• Resolution Plan: The resolution plan for Karkinos was approved by the National Company Law Tribunal (NCLT), Mumbai Bench, without requiring additional regulatory approvals.

Karkinos partners with hospitals to provide oncology services such as testing and radiation therapy. The company is involved in cutting-edge cancer research and provides financial guidance and community support to cancer patients.

Karkinos is setting up a 150-bed multispecialty cancer hospital in Imphal, Manipur.

The acquisition aims to expand Reliance's health services business portfolio and enhance its capabilities in cancer care.

To recall, earlier this month, Infosys has acquired a 20% minority stake in the healthcare deep-tech startup 4baseCare, for Rs 8.3 crore,which too is focused on developing oncology solutions.

In this month only, Bengaluru-based HealthCare Global Enterprises Limited (HCG), one of the largest cancer care networks in India, and consulting giant Accenture have announced a collaboration to accelerate cancer research and care using advanced AI technologies, including generative AI and deep learning on multi-dimensional and multi-omic patient data. 

Accenture and Bengaluru-based HCG Partner for Advance AI-powered Cancer Research, Care

HealthCare Global Enterprises Limited (HCG), one of the largest cancer care networks in India, and Accenture have announced a collaboration to accelerate cancer research and care using advanced AI technologies, including generative AI and deep learning on multi-dimensional and multi-omic patient data. This innovative, data-driven program aims to enhance early detection and treatment for various types of cancer in South Asia.

The collaboration will leverage AI, including generative AI and deep learning, to analyze multi-dimensional and multi-omic patient data.

This strategic partnership combines Accenture’s global expertise and talent in data and AI including AI/ML, generative AI, and quantum computing with deep clinical insights from HCG in oncology to enable early detection and treatment for various types of cancer.

Accenture will use advanced technologies such as image analysis software, informatics, and novel algorithms to study molecular alterations and develop new drug targets.

The initiative aims to advance the quality of therapy and care by enabling new treatment algorithms for precision medicine.

The collaboration will showcase data-driven clinical practice and enhance the overall efficiency of patient care. This partnership is expected to play a pivotal role in cancer research and care, addressing the needs of patients and benefiting the global healthcare industry.

Dr. B. S. Ajaikumar, Executive Chairman of HCG, emphasized the importance of tech-driven advancements in research and academics for optimizing cancer care.

Headquartered in Bengaluru, HCG has also worked with Microsoft to implement cloud-based solutions and AI technologies for better data management and analysis in oncology. In April 2022, HCG launched Extended Reality Lab using the Microsoft HoloLens 2 at the HCG Cancer Hospital Bengaluru.

HCG operates multiple entities, including tertiary care hospitals, cancer care centers, and diagnostic centers.

Senthil Ramani, global lead of Data and AI at Accenture, said, “Next-gen computing, including generative AI, combined with deep biological and clinical expertise, can play a pivotal role in cancer research and care, addressing needs of patients and benefiting the global healthcare industry at large. Together with HCG, we are blending our global expertise in data and AI along with life sciences R&D to rapidly and accurately improve decision-making for the treatment and care for cancer patients in South Asia, and across the world.”

Param Hansa Centre for Computational Oncology Launched at IISc

Param Hansa Philanthropies (PHP) has made a generous commitment to support the setting up of a Centre for Computational Oncology at the Indian Institute of Science (IISc). The Centre was officially launched at a ceremony held on 2 November 2023. It marks a major leap forward in the quest to integrate cutting-edge computational methodologies with ground breaking cancer research.

The Param Hansa Centre for Computational Oncology (PHCCO) will foster research in predictive and quantitative mathematical models of cancer progression, metastasis, and tumor relapse, to identify the underlying fundamental dynamics of these multi-scale processes and to eventually improve patient outcomes in the clinic. The Centre aims to nurture an active community of future leaders in computational oncology in India, through inter-institutional, cross-disciplinary collaborations among researchers in academia, medicine, and industry. The Center will be led by Mohit Kumar Jolly, Associate Professor at the Department of Bioengineering, who heads the Cancer Systems Biology research group at IISc.

Param Hansa Centre – IISc

The partnership was facilitated through the IISc Foundation, a non-profit entity set up in the USA, to support research and infrastructure development at IISc. Param Hansa Philanthropies will support the Centre with USD 1 million over the next seven years.

Speaking at the launch ceremony, Mr Dheeraj Pandey, Founding Director of PHP, said, “We, at Param Hansa Philanthropies, are delighted and proud today at the launch of this new initiative aimed at significant, long-term impact in the area of computational oncology, supporting IISc in its mission. We believe in utilising the power of science and data sciences to create deep, meaningful outcomes for cancer research in India and elsewhere. With this long-term collaboration with IISc, we look forward to contributing to the fight against cancer in India and elsewhere, and simultaneously building a cadre of young scientists who, over time, will make a significant contribution to research and training future researchers in this field.”

Prof Govindan Rangarajan, Director of IISc, said, “We are very grateful to Param Hansa Philanthropies for their generous contribution to support research in the emerging area of computational oncology. At IISc, we are constantly seeking to push frontiers in cutting-edge research and encourage cross-disciplinary partnerships that solve pressing clinical challenges. We look forward to the exciting projects and solutions that will emerge from this new Centre.”

About Param Hansa Philanthropies:

Param Hansa Philanthropies (PHP) is Dheeraj and Swapna Pandey’s private foundation in the USA. PHP aims to partner closely with universities and research organizations to foster efforts in the computing + life sciences space, support active development of scientific ideas that revolutionize new frontiers, and harness the power of tech to solve healthcare related problems and help create a better future for human society. PHP’s existing collaborations include partnerships with the University of Texas, Austin and Stanford University. PHP-India began operations recently with the launch of its office in Bengaluru, India, and the establishment of the Param Hansa Centre for Computational Oncology at IISc is its first India partnership. PHCCO, in partnership with IISc, is an outcome of PHP’s deep, long-term commitment to translational research at the intersection of healthcare and technology.

About IISc Foundation:

IISc Foundation is a platform to support IISc’s drive towards global excellence in engineering education and research. It is an IRS-approved tax-exempt 501(c)(3) non-profit entity established and managed by volunteer IISc alumni to raise endowment funds for IISc from alumni, corporations, and foundations in the USA.

Morgan Stanley PE Acquires Gurugram based Clearmedi Healthcare, A Cancer Care Hospitals Chain for $35 Mn

Morgan Stanley’s private equity arm has acquired a majority stake in Gurugram-based oncology/cancer care hospital chain, for reportedly $35 Million.

ClearMedi Healthcare is a joint venture between Medipass (La Repubblica group) S.r.l. Italy, KOS S.p.A. Italy and Clearview Healthcare India.

Morgan Stanley PE, along with the promoters of the healthcare chain, bought out 100% stake in the healthcare chain from Italy's KOS Group.

The acquisition deal includes both stake purchase and infusion of fresh equity into the company, said a report by Economic Times. However, specific details like proportion of stakes picked from the KOS Group and how much came into the company as fresh equity remain undisclosed at present.

Founded in 2010, by Shashi Kant Baliyan, ClearMedi is in business of managing complex clinical services running and operating full clinical setups/ Hospitals. From unit operations of Oncology, Nuclear Medicine and Radiology, we are now Operating and Managing stand-alone Super Specialty Hospitals.

The hospital chain has over 350+ Hospital beds autonomously managed by it in different self-sufficient Tertiary-care Hospitals fully managed by ClearMedi.

For Its Blood Test to Detect Early-stage Prostate Cancer, Mumbai-based Datar Cancer Genetics Gets 'Breakthrough Designation' from the US FDA

Representational Image

The US FDA grants the coveted Breakthrough Designation for Early-Stage Prostate Cancer Detection Blood Test Developed in India by Datar Cancer Genetics

It is the first blood test able to detect early-stage Prostate Cancer with high accuracy in men aged 55 years and above

Datar Cancer Genetics today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Designation' for its blood test to detect early-stage prostate cancer. This is the second test from Datar Cancer Genetics that has received the Breakthrough Device Designation from the US FDA. Late last year, Datar Cancer Genetics’ breast cancer detection test became the first such test to receive the designation.

This is the first blood test for men which can detect early-stage prostate cancer with high accuracy. The test is available in India by the name of Easycheck. Men with serum PSA of more than 3 ng / mL can avail of this test in consultation with their physician. The test requires 5 ml blood and does not involve exposure to radiation or any of the discomforts of a digital rectal examination. 

The blood test is based on the detection of Circulating Tumor Cells (CTCs) specific to prostate adenocarcinoma. The test can detect early-stage prostate cancers with more than 99% accuracy without any false positives. The test has been validated in large clinical studies involving healthy males and prostate cancer patients.

In India, about 35,000 men were detected with prostate cancer in 2020 and this number is slated to increase every year, as is the case for all cancers due to various risk factors. Unfortunately, most prostate cancer cases are detected at late stages (III or IV) where it has spread to other organs. In such cases, curative surgeries that can remove the cancerous tissue are not viable options, and treatment involves long-term administration of anticancer drugs to manage the disease. If detected at early stages where cancer has not spread out of the prostate, prostate cancer has a very high (>99%) chance of being cured.

"About 75% of prostate biopsies are benign and with foreknowledge, these could be potentially avoided. The new blood test by the Datar team will help Doctors decide precisely the patients who need a biopsy and who do not. This is a very significant scientific advancement in the complex field of liquid biopsies coming from India. I congratulate the Datar team for their exemplary work and achievement," said Dr. Sewanti Limaye, Director of Medical and Precision Oncology and Oncology Research, Sir HN Reliance Foundation Hospital and Research Centre, Mumbai.

"It is a landmark acknowledgement that the US FDA has recognized the potential benefits of our 'first in the world' prostate cancer detection test. The highly coveted 'Breakthrough Designation' is granted after very rigorous evaluation. We take great pride in the fact that this test has been wholly developed in India and by Indian scientists and clinicians. This is our ongoing contribution to the Prime Minister's 'Atmanirbhar Bharat' mission after the breakthrough breast cancer detection test and is further intended to augment the global fight against cancer," said Mr. Rajan Datar, Chairman of the Company.

Appreciably, getting the test does not involve having to go to any hospital or health centre and waiting for appointments. The blood collection for this test can be done in the convenience and privacy of one's home or office after which the patient can go about their routine work. From the patient's point of view, the whole process is very non-intrusive.

The test is already available in Europe and is CE marked. The Company is in discussions with several leading healthcare providers for ready accessibility in India.

About Datar Cancer Genetics

Datar Cancer Genetics is a global oncology research and applications company that is spearheading the development of non-invasive technologies for improved detection, treatment and management of cancer. The Company's state-of-the-art cancer research centre is NABL, ISO, CAP and CLIA accredited. The Company serves cancer patients and suspected cases in the UK, European Union, United States, GCC, and India.

Biotech Startup Mestastop Solutions Raises 1.3 Cr from CIIE.CO to Map the Anatomy of Cancer Using Deep-dive Analysis

• Mestastop aims to make a difference by understanding metastasis biology and addressing it, for both diagnostics and drug discovery
• Using their predictive analogy, the company is also building a platform that will diagnose patients that have a higher chance of cancer metastasis

Bengaluru-based Biotechnology startup Mestastop Solutions  Pvt. Ltd has raised a new INR 1.3 Crores seed funding round, led by CIIE.CO and including participation from IKP Knowledge Park and Angels. 

Mestastop will use the funding to scale its AI-based platform METSCAN, which characterizes cancer cells using patient data samples and their assay panels to understand the cell behaviour. It will further be utilised for running PoC animal model studies to validate proof of concept for Cancer drug discovery and repurposing.

Founded in the year 2018, the start-up’s unique edge is to be “the metastasis specialists”, by creating a world-class R&D leveraging the unique strengths of being in India. The company is based in Bengaluru, where they are bringing together a cross-functional team, trained in discovery, diagnostics and AI, supported by the state-of-the-art infrastructure available in India’s best bioscience incubators. Dr Arnab Roy Chowdhury and his wife Dr Debabani Roy Chowdhury are the brains behind Mestastop which looks at bringing a revolution in cancer treatment.

Cancer metastasis, a complex biological process, is responsible for 90% of cancer-related deaths. According to Emergen Research 2020 report, the Global Metastatic Cancer Treatment Market is projected to be worth USD 111.16 Billion by 2027. Mestastop is creating a cancer metastasis focused  platform which uses wet lab biology and predictive analytics to identify and distinguish unique properties of metastasis and leverage them for drug discovery and patient treatment. Mestastop has mimicked metastasis biology in multiple steps, each being represented by a cell-based functional assay. Summatively, these assays provide a biological model that will expedite the in vitro drug discovery efforts against metastasis. The colorectal and triple negative breast cancer-based platform is ready and Mestastop is normalizing the colorectal platform with patient sample data.

Speaking on the announcement, Dr Arnab Roy Chowdhury, Founder & CEO, Mestastop states, “An evolutionary disease like cancer cannot be holistically targeted without targeting metastasis, a process that is complex and is yet to be fully understood. We have successfully created tools and platforms to decipher this biology, translated it with patient data, and then into animal models completing our first phase. Now we endeavour on the bigger journey of using these tools for first-in-class metastasis drug discovery and predictive diagnostics, that will give terminal cancer patients a second shot at life, further reinforcing India’s image as one of the pioneering innovation hubs in the Biotech world."

Currently, the company has initiated testing patient data samples as well as animal model validation. In addition to this, one international patent has been filed and another provisional patent  is currently being drafted.

“Globally, there are several startups focusing on cancer diagnostics and drug discovery. Mestastop is creating a niche for itself using assay and genetically engineered cell-based approaches to develop an AI-based platform to predict metastasis and we are delighted to partner with them on this journey. We believe that their platform will play an instrumental role in changing cancer treatment in India and the world around,” Said Chintan Antani, AVP, Seed Investments, CIIE.CO.

Mestastop has developed three proprietary platforms - METAssay, METSCAN, and METVivo to unravel metastasis drug discovery and predictive diagnostics. The company is currently working on validating its platforms on a larger sample of patient tumours that will empower its IP creation. Previously the company also received an investment from Vistari Ventures and Mumbai Angels.

About CIIE.CO:

CIIE.CO is The Innovation Continuum. This continuum spreads across incubation, acceleration, seed and growth funding, and research. Founded at IIM Ahmedabad in 2002, as an academic centre, CIIE.CO has grown and pivoted to include acceleration, incubation, investment, research and publication. Overall, we have aimed at filling the multiple, ever-evolving gaps in the Indian innovation-driven entrepreneurship space in many ways. Among various initiatives, CIIE.CO has conceptualised and hosted India’s first accelerator, created India’s first and so far the only cleantech-focused fund, accelerated over 1000 entrepreneurs, invested in over 160 startups, inspired over a million with their publications, including Stay Hungry Stay Foolish.

All the initiatives on the innovation continuum are aimed at supporting fearless, innovation-driven entrepreneurs. Working with like-minded partners like corporates, government agencies, investors and academia, helps us push harder towards co-creating exponential change.

About MestaStop:

Mestastop Solutions is a deep-dive biotech start-up focussed around cancer metastasis, which involves the spreading of the tumor that is responsible for 90% of cancer deaths. Mestastop has developed three proprietary platforms METAssay™, METSCAN™, and METVivo™ to unravel metastasis drug discovery and predictive diagnostics. The company is currently working on validating its platforms on a larger sample of patient tumors that will empower its IP creation.

Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-breaking Cancer Research

ESMO, the leading organisation for medical oncology, has launched an important new service for rapidly disseminating research to accelerate the transition of results into practice for the benefit of cancer patients.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005495/en/

 

(Graphic: ESMO)

“In a world that runs fast, timeliness in bringing research advances to patients is critical. The lessons that we have learnt from the COVID-19 pandemic have taught us that we need to be creative in sharing research results, and we certainly don’t have to wait for the two or three times in the year when major oncology congresses take place,” says Solange Peters, ESMO President.

 

ESMO Virtual Plenaries will combine concise presentations of new data, insightful discussion and audience Q&A in live, easy-to-access, 60-minute online sessions at convenient times across international time zones. They will remain available on OncologyPRO, ESMO’s online resource portal, for subsequent viewing.

Every month, latest, original scientific data will be presented from randomised phase III oncology trials or phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.

“By timely presentation of clinical and scientific data, ESMO Virtual Plenaries will be complementary to and enhance the value of conventional scientific congresses, whilst adhering to the principles of peer review, analysis and audience interaction,” says George Pentheroudakis, ESMO Chief Medical Officer.

A maximum of two abstracts will be accepted for presentation each month (except September and November when ESMO hosts major congresses). Abstracts will be original data from international investigators, selected by appropriate independent ESMO specialists. After presentation and discussion in ESMO Virtual Plenaries, abstracts will be published in Annals of Oncology and will be eligible for encore presentation at the next ESMO Congress.

The first ESMO Virtual Plenary is on Friday, 19 February, 1300 CET  

Efficacy of everolimus in patients with HR+/HER2- high risk early-stage breast cancer

 

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology. ESMO Members or anyone with an already existing free ESMO Account will be able to log in and watch using their existing ESMO Account.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005495/en/